JP2013520166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520166A5 JP2013520166A5 JP2012553874A JP2012553874A JP2013520166A5 JP 2013520166 A5 JP2013520166 A5 JP 2013520166A5 JP 2012553874 A JP2012553874 A JP 2012553874A JP 2012553874 A JP2012553874 A JP 2012553874A JP 2013520166 A5 JP2013520166 A5 JP 2013520166A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- polypeptide
- rage
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims 28
- 102000037865 fusion proteins Human genes 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims 22
- 230000035772 mutation Effects 0.000 claims 9
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 230000013595 glycosylation Effects 0.000 claims 5
- 238000006206 glycosylation reaction Methods 0.000 claims 5
- 102000049409 human MOK Human genes 0.000 claims 5
- 102000004961 Furin Human genes 0.000 claims 4
- 108090001126 Furin Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 2
- 102220598894 Reduced folate transporter_N58Q_mutation Human genes 0.000 claims 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 108020001756 ligand binding domains Proteins 0.000 claims 2
- 102200054322 rs121909342 Human genes 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005230 Leg Ulcer Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000036252 glycation Effects 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30570610P | 2010-02-18 | 2010-02-18 | |
| US61/305,706 | 2010-02-18 | ||
| PCT/US2010/032270 WO2011102845A1 (en) | 2010-02-18 | 2010-04-23 | Rage fusion protein compositions and methods of use |
| USPCT/US2010/032270 | 2010-04-23 | ||
| PCT/US2010/053157 WO2011102860A1 (en) | 2010-02-18 | 2010-10-19 | Rage fusion protein compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013520166A JP2013520166A (ja) | 2013-06-06 |
| JP2013520166A5 true JP2013520166A5 (enExample) | 2013-12-05 |
Family
ID=44483217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553874A Pending JP2013520166A (ja) | 2010-02-18 | 2010-10-19 | Ｒａｇｅ融合タンパク質及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130142792A1 (enExample) |
| EP (1) | EP2536750A1 (enExample) |
| JP (1) | JP2013520166A (enExample) |
| CA (1) | CA2789244A1 (enExample) |
| TW (1) | TW201141507A (enExample) |
| WO (2) | WO2011102845A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9938353B2 (en) | 2011-06-24 | 2018-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| US10478508B2 (en) * | 2012-01-10 | 2019-11-19 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| EP4219536A3 (en) | 2012-04-30 | 2023-08-23 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| PT2970512T (pt) * | 2013-03-12 | 2019-01-17 | Biocon Ltd | Proteínas de fusão imunomoduladoras e métodos para produção das mesmas |
| US11547743B2 (en) * | 2014-04-28 | 2023-01-10 | Eisai R&D Management Co., Ltd. | Lyophilized formulation of HGF |
| HUE055414T2 (hu) | 2016-03-17 | 2021-11-29 | Eisai R&D Man Co Ltd | Eljárás aktivált hepatocita növekedési faktor (HGF) elõállítására |
| EP3849578A4 (en) * | 2018-09-14 | 2022-06-22 | Bioage Labs, Inc. | Rage fusion proteins with improved stability and ligand binding affinity and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
| US6825164B1 (en) | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| PT1355919E (pt) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| DK1436003T3 (da) * | 2001-05-24 | 2010-03-15 | Zymogenetics Inc | TACI-immunoglobulin-fusionsproteiner |
| CN1798767B (zh) * | 2003-04-10 | 2011-02-16 | 晶面生物技术公司 | 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期 |
| WO2004100890A2 (en) * | 2003-05-09 | 2004-11-25 | The Trustees Of Columbia University In The City Of New York | Rage g82s-related methods and compositions for treating inflammatory disorders |
| AU2004251599A1 (en) | 2003-05-20 | 2005-01-06 | Transtech Pharma, Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| MX2007001559A (es) * | 2004-08-03 | 2007-04-10 | Transtech Pharma Inc | Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso. |
| US20070087406A1 (en) * | 2005-05-04 | 2007-04-19 | Pei Jin | Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same |
| SG171670A1 (en) * | 2006-05-05 | 2011-06-29 | Transtech Pharma Inc | Rage fusion proteins, formulations, and methods of use thereof |
| ES2564634T3 (es) * | 2007-06-14 | 2016-03-28 | Galactica Pharmaceuticals, Inc. | Proteínas de fusión de RAGE |
| DE102008037312B3 (de) | 2008-08-11 | 2010-02-18 | Emz-Hanauer Gmbh & Co. Kgaa | Elektrischer Schalter, insbesondere in Mikroschalter-Bauform |
-
2010
- 2010-04-23 WO PCT/US2010/032270 patent/WO2011102845A1/en not_active Ceased
- 2010-10-19 JP JP2012553874A patent/JP2013520166A/ja active Pending
- 2010-10-19 CA CA2789244A patent/CA2789244A1/en not_active Abandoned
- 2010-10-19 US US13/062,395 patent/US20130142792A1/en not_active Abandoned
- 2010-10-19 WO PCT/US2010/053157 patent/WO2011102860A1/en not_active Ceased
- 2010-10-19 EP EP10773766A patent/EP2536750A1/en not_active Withdrawn
-
2011
- 2011-02-18 TW TW100105575A patent/TW201141507A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520166A5 (enExample) | ||
| TWI760333B (zh) | Ｇｄｆ１５融合蛋白及其用途 | |
| JP2011501959A5 (enExample) | ||
| US9260496B2 (en) | Fibronectin based scaffold domain proteins that bind IL-23 | |
| JP2008508882A5 (enExample) | ||
| JP2011525363A5 (enExample) | ||
| CN107266579A (zh) | 用于治疗代谢疾病的融合蛋白 | |
| JP2009201525A5 (enExample) | ||
| CN109836504A (zh) | 一种治疗代谢疾病的多结构域活性蛋白 | |
| EP2968587A2 (en) | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto | |
| CN101389648A (zh) | 肽胃泌酸调节素衍生物 | |
| CN113292646B (zh) | Glp-1/胰高血糖素双重激动剂融合蛋白 | |
| CN108350069B (zh) | 针对il-23的多肽 | |
| AU2016344134A1 (en) | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs | |
| WO2015061351A1 (en) | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use | |
| KR20210024081A (ko) | 당뇨병을 위한 gip/glp1 공효능제의 사용 방법 | |
| WO2024238920A9 (en) | Methods of using activin receptor type ii variants | |
| US20220119448A1 (en) | Artificial recombinant protein for improving performance of active protein or polypeptide and use thereof | |
| AU2009265327A1 (en) | Insulin fusion polypeptides | |
| JP2016019527A (ja) | Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 | |
| WO2007146171A2 (en) | Purified high molecular weight adiponectin and uses thereof | |
| Tutone et al. | Leptin and the OB-receptor as anti-obesity target: recent in silico advances in the comprehension of the protein-protein interaction and rational drug design of anti-obesity lead compounds | |
| CN114617956B (zh) | 一种高效降糖的蛋白质药物 | |
| CN103601808B (zh) | 钠肽、制备方法及其在制备基因工程药物中的应用 | |
| CN105085659A (zh) | 一种重组利钠肽及其制备方法 |